Next Article in Journal
Optimization of Advanced Live-Cell Imaging through Red/Near-Infrared Dye Labeling and Fluorescence Lifetime-Based Strategies
Previous Article in Journal
Histone Demethylase KDM7A Contributes to the Development of Hepatic Steatosis by Targeting Diacylglycerol Acyltransferase 2
Review

BET Proteins as Attractive Targets for Cancer Therapeutics

1
Department of Rheumatology, Medical University of Lodz, 90-050 Lodz, Poland
2
Department of Molecular Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-236 Lodz, Poland
*
Author to whom correspondence should be addressed.
Academic Editor: Agnieszka Zdzislawa Robaszkiewicz
Int. J. Mol. Sci. 2021, 22(20), 11102; https://doi.org/10.3390/ijms222011102
Received: 2 September 2021 / Revised: 4 October 2021 / Accepted: 8 October 2021 / Published: 14 October 2021
(This article belongs to the Special Issue Transcription in Cancer Initiation and Progression)
Transcriptional dysregulation is a hallmark of cancer and can be an essential driver of cancer initiation and progression. Loss of transcriptional control can cause cancer cells to become dependent on certain regulators of gene expression. Bromodomain and extraterminal domain (BET) proteins are epigenetic readers that regulate the expression of multiple genes involved in carcinogenesis. BET inhibitors (BETis) disrupt BET protein binding to acetylated lysine residues of chromatin and suppress the transcription of various genes, including oncogenic transcription factors. Phase I and II clinical trials demonstrated BETis’ potential as anticancer drugs against solid tumours and haematological malignancies; however, their clinical success was limited as monotherapies. Emerging treatment-associated toxicities, drug resistance and a lack of predictive biomarkers limited BETis’ clinical progress. The preclinical evaluation demonstrated that BETis synergised with different classes of compounds, including DNA repair inhibitors, thus supporting further clinical development of BETis. The combination of BET and PARP inhibitors triggered synthetic lethality in cells with proficient homologous recombination. Mechanistic studies revealed that BETis targeted multiple essential homologous recombination pathway proteins, including RAD51, BRCA1 and CtIP. The exact mechanism of BETis’ anticancer action remains poorly understood; nevertheless, these agents provide a novel approach to epigenome and transcriptome anticancer therapy. View Full-Text
Keywords: BET; BETi; cancer; DNA repair; homologous recombination; transcription BET; BETi; cancer; DNA repair; homologous recombination; transcription
Show Figures

Figure 1

MDPI and ACS Style

Sarnik, J.; Popławski, T.; Tokarz, P. BET Proteins as Attractive Targets for Cancer Therapeutics. Int. J. Mol. Sci. 2021, 22, 11102. https://doi.org/10.3390/ijms222011102

AMA Style

Sarnik J, Popławski T, Tokarz P. BET Proteins as Attractive Targets for Cancer Therapeutics. International Journal of Molecular Sciences. 2021; 22(20):11102. https://doi.org/10.3390/ijms222011102

Chicago/Turabian Style

Sarnik, Joanna, Tomasz Popławski, and Paulina Tokarz. 2021. "BET Proteins as Attractive Targets for Cancer Therapeutics" International Journal of Molecular Sciences 22, no. 20: 11102. https://doi.org/10.3390/ijms222011102

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop